{"name":"Fundacion SEIMC-GESIDA","slug":"fundacion-seimc-gesida","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"oncology","drugs":[{"name":"ELV/COBI/FTC/TAF","genericName":"ELV/COBI/FTC/TAF","slug":"elv-cobi-ftc-taf","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Ritonavir boosted Atazanavir + Lamivudine","genericName":"Ritonavir boosted Atazanavir + Lamivudine","slug":"ritonavir-boosted-atazanavir-lamivudine","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"AZT+3TC+ABV (Trizivir)","genericName":"AZT+3TC+ABV (Trizivir)","slug":"azt-3tc-abv-trizivir","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Bezlotoxumab Injection [Zinplava]","genericName":"Bezlotoxumab Injection [Zinplava]","slug":"bezlotoxumab-injection-zinplava","indication":"Prevention of Clostridioides difficile infection recurrence","status":"phase_2"},{"name":"DTG/3TC/ABC + ELV/COBI/FTC/TAF","genericName":"DTG/3TC/ABC + ELV/COBI/FTC/TAF","slug":"dtg-3tc-abc-elv-cobi-ftc-taf","indication":"HIV-1 infection in treatment-naïve or treatment-experienced adults","status":"marketed"},{"name":"Dolutegravir/Lamivudine as a single pill","genericName":"Dolutegravir/Lamivudine as a single pill","slug":"dolutegravir-lamivudine-as-a-single-pill","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"},{"name":"Emtricitabine/tenofovir or abacavir/lamivudine","genericName":"Emtricitabine/tenofovir or abacavir/lamivudine","slug":"emtricitabine-tenofovir-or-abacavir-lamivudine","indication":"HIV-1 infection (as part of combination antiretroviral therapy)","status":"marketed"},{"name":"Ritonavir boosted Atazanavir + 2 NRTIs","genericName":"Ritonavir boosted Atazanavir + 2 NRTIs","slug":"ritonavir-boosted-atazanavir-2-nrtis","indication":"HIV-1 infection in treatment-naïve and treatment-experienced patients","status":"marketed"},{"name":"Symtuza® (TAF/FTC/DRV/c)","genericName":"Symtuza® (TAF/FTC/DRV/c)","slug":"symtuza-taf-ftc-drv-c","indication":"HIV-1 infection in treatment-naïve and treatment-experienced adults","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"HPV9v","genericName":"HPV9v","slug":"hpv9v","indication":"Prevention of cervical cancer and precancerous lesions caused by HPV types 16, 18, 31, 33, 45, 52, and 58","status":"marketed"}]}],"pipeline":[{"name":"ELV/COBI/FTC/TAF","genericName":"ELV/COBI/FTC/TAF","slug":"elv-cobi-ftc-taf","phase":"marketed","mechanism":"This is a fixed-dose combination of four antiretroviral agents that work together to suppress HIV replication through multiple mechanisms: elvitegravir inhibits integrase, cobicistat boosts drug levels, and emtricitabine and tenofovir alafenamide inhibit reverse transcriptase.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults"],"catalyst":""},{"name":"Ritonavir boosted Atazanavir + Lamivudine","genericName":"Ritonavir boosted Atazanavir + Lamivudine","slug":"ritonavir-boosted-atazanavir-lamivudine","phase":"marketed","mechanism":"This combination inhibits HIV protease and reverse transcriptase to block viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"AZT+3TC+ABV (Trizivir)","genericName":"AZT+3TC+ABV (Trizivir)","slug":"azt-3tc-abv-trizivir","phase":"marketed","mechanism":"Trizivir is a fixed-dose combination of three nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase to prevent viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Bezlotoxumab Injection [Zinplava]","genericName":"Bezlotoxumab Injection [Zinplava]","slug":"bezlotoxumab-injection-zinplava","phase":"phase_2","mechanism":"Inhibits Clostridioides difficile toxin","indications":["Prevention of Clostridioides difficile infection recurrence"],"catalyst":""},{"name":"DTG/3TC/ABC + ELV/COBI/FTC/TAF","genericName":"DTG/3TC/ABC + ELV/COBI/FTC/TAF","slug":"dtg-3tc-abc-elv-cobi-ftc-taf","phase":"marketed","mechanism":"This is a fixed-dose combination of two antiretroviral regimens that inhibit HIV reverse transcriptase and integrase to suppress viral replication.","indications":["HIV-1 infection in treatment-naïve or treatment-experienced adults"],"catalyst":""},{"name":"Dolutegravir/Lamivudine as a single pill","genericName":"Dolutegravir/Lamivudine as a single pill","slug":"dolutegravir-lamivudine-as-a-single-pill","phase":"marketed","mechanism":"Dolutegravir inhibits HIV integrase to prevent viral DNA integration into the host genome, while lamivudine inhibits reverse transcriptase to block HIV replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults","HIV-1 infection as a maintenance therapy"],"catalyst":""},{"name":"Emtricitabine/tenofovir or abacavir/lamivudine","genericName":"Emtricitabine/tenofovir or abacavir/lamivudine","slug":"emtricitabine-tenofovir-or-abacavir-lamivudine","phase":"marketed","mechanism":"These are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral RNA from being converted into DNA and integrated into host cells.","indications":["HIV-1 infection (as part of combination antiretroviral therapy)","HIV-1 pre-exposure prophylaxis (PrEP) for emtricitabine/tenofovir"],"catalyst":""},{"name":"HPV9v","genericName":"HPV9v","slug":"hpv9v","phase":"marketed","mechanism":"HPV9v is a 9-valent human papillomavirus vaccine that stimulates immune responses against nine HPV types to prevent infection and HPV-related cancers.","indications":["Prevention of cervical cancer and precancerous lesions caused by HPV types 16, 18, 31, 33, 45, 52, and 58","Prevention of genital warts caused by HPV types 6 and 11","Prevention of other HPV-related anogenital and oropharyngeal cancers"],"catalyst":""},{"name":"Ritonavir boosted Atazanavir + 2 NRTIs","genericName":"Ritonavir boosted Atazanavir + 2 NRTIs","slug":"ritonavir-boosted-atazanavir-2-nrtis","phase":"marketed","mechanism":"Atazanavir inhibits HIV protease to prevent viral replication, while ritonavir boosts its blood levels, and the two NRTIs block reverse transcriptase to further suppress HIV.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced patients"],"catalyst":""},{"name":"Symtuza® (TAF/FTC/DRV/c)","genericName":"Symtuza® (TAF/FTC/DRV/c)","slug":"symtuza-taf-ftc-drv-c","phase":"marketed","mechanism":"Symtuza is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and protease to prevent viral replication.","indications":["HIV-1 infection in treatment-naïve and treatment-experienced adults"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":10,"phaseCounts":{"marketed":9,"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}